NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well ...

The study introduces a novel "multi-route" administration protocol for Wharton’s Jelly-derived Mesenchymal Stem Cells (WJ-MSCs). Unlike previous trials that relied on a single delivery method, this ...

For patients who are unable to take medication by mouth, the tablet may be dispersed in a dosing cup and administered via NG tube or G tube. The Food and Drug Administration (FDA) has approved an ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...

FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability ...